TABLE 2.
Participant Characteristics by Report of HT Side Effects
| Reported side effects (N=67) |
No side effects reported (N=31) |
P- value |
|
|---|---|---|---|
| Age, years, mean (SD) | 58 (10.2) | 60 (12.1) | 0.31 |
| Race | 0.06 | ||
| Non-white | 26 (81%) | 6 (19%) | |
| White | 41 (62%) | 25 (38%) | |
| Education | 0.96 | ||
| High school or below | 17 (25%) | 8 (25%) | |
| College or above | 50 (75%) | 23 (75%) | |
| Social Support | 0.54 | ||
| A Lot | 59 (88%) | 26 (84%) | |
| Somewhat or less | 8 (12%) | 5 (16%) | |
| Median HT duration (months) | 20 | 36 | 0.58 |
| HT duration | 0.20 | ||
| ≤12 months | 30 (45%) | 8 (26%) | |
| 12-36 months | 22 (33%) | 13 (42%) | |
| > 36 months | 15 (22%) | 10 (32%) | |
| HT necessity score, mean (range) | 10.8 (0-20) | 10.9 (4-16) | 0.91 |
| HT concern score, mean (range) | 8.0 (0-16) | 6.8 (0-12) | 0.12 |
| HT purpose | 0.90 | ||
| Prevent | 27 (42%) | 13 (42%) | |
| Treat | 10 (15%) | 4 (13%) | |
| Prevent and Treat | 25 (39%) | 11 (36%) | |
| Neither | 2 (2%) | 2 (3%) | |
| HT adherence | 50 (75%) | 25 (81%) | 0.51 |
| Reported discussion of side effects with a provider | 43 (88%) | 6 (12%) | 0.03 |
| Patient-Provider Communication | |||
| Total score, mean (range) | 39.7 (24-45) | 40.1 (34-45) | 0.73 |
| Information subscale, mean (range) | 13.2 (5-15) | 13.2 (3-15) | 0.94 |
| Affective subscale, mean (range) | 14.1 (7-15) | 14.1 (9-15) | 0.95 |
| Communication subscale, mean (range) | 12.0 (3-15) | 12.8 (7-15) | 0.25 |
HT=hormonal therapy